Clinical Trial

Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2017-03-08; most recent amendment 2025-10-27.
Status change: Active, Not Recruiting → Recruiting 2023-11-16
Status change: Recruiting → Active, Not Recruiting 2021-04-13
Status change: Not Yet Recruiting → Recruiting 2017-09-29
Trial Details
NCT Number NCT03080974
Lead Sponsor University of Louisville
Conditions Pancreatic Adenocarcinoma
Enrollment 10 participants
Start Date 2017-08-14
Primary Completion 2028-06-01 (estimated)
Study Completion 2029-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-10-29